Ipsen

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:05:05 21/06/2024 pm IST			5-day change	1st Jan Change
113.9 ^EUR	-2.57%		-5.48%	+5.56%

12/06	Ipsen: share price soars, UBS confirms its recommendation	CF
12/06	IPSEN : UBS remains Buy after FDA approval	CF

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

May 28, 2024 at 09:30 pm IST

Ipsen S.A. at its Annual General Meeting held on 28 May 2024 approved the payment of a dividend of ?1.20 per share. This dividend will be paid on 3 June 2024, the ex-date being 30 May 2024.

Latest news about Ipsen

Ipsen: share price soars, UBS confirms its recommendation	12/06	CF
IPSEN : UBS remains Buy after FDA approval	12/06	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	11/06	CI
Ipsen: FDA grants approval for treatment	11/06	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	11/06	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	11/06	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	11/06	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	11/06	RE
US FDA approves Genfit and Ipsen's liver disease drug	11/06	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	07/06	MT
Ipsen: research partnership with Marengo extended	07/06	CF
Ipsen Hires New Chief Corporate Affairs Officer	06/06	MT
Ipsen: new Chief Corporate Affairs Officer	06/06	CF
Ipsen: new positive data in PBC	05/06	CF
Ipsen: mandate to an ISP for share buybacks	03/06	CF
Ipsen: new employee shareholding operation	31/05	CF
Ipsen S.A. Approves Dividend, Payable on 3 June 2024	28/05	CI
Ipsen: share price up, analyst raises target	14/05	CF
IPSEN : Barclays raises its target price	14/05	CF
Ipsen Announces Executive Changes	02/05	CI
Ipsen: new President for North America	02/05	CF
IPSEN : Better-than-expected Q1; guidance unchanged	24/04
Transcript : Ipsen S.A., Q1 2024 Sales/ Trading Statement Call, Apr 24, 2024	24/04
Ipsen: sales up 11% in Q1	24/04	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	22/04	MT

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 08:20 pm IST

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

113.9 EUR

Average target price

127.3 EUR

Spread / Average Target

+11.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+5.56%	10.05B
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals